BR112018075371A2 - usos terapêuticos de um inibidor de c-raf - Google Patents

usos terapêuticos de um inibidor de c-raf

Info

Publication number
BR112018075371A2
BR112018075371A2 BR112018075371-8A BR112018075371A BR112018075371A2 BR 112018075371 A2 BR112018075371 A2 BR 112018075371A2 BR 112018075371 A BR112018075371 A BR 112018075371A BR 112018075371 A2 BR112018075371 A2 BR 112018075371A2
Authority
BR
Brazil
Prior art keywords
relates
present
combination
raf
inhibitor
Prior art date
Application number
BR112018075371-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Caponigro Giordano
Cooke Vesselina
Helena Mais Anna
Nauwelaerts Heidi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112018075371A2 publication Critical patent/BR112018075371A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112018075371-8A 2016-06-10 2017-06-08 usos terapêuticos de um inibidor de c-raf BR112018075371A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348720P 2016-06-10 2016-06-10
US62/348,720 2016-06-10
PCT/IB2017/053405 WO2017212442A1 (en) 2016-06-10 2017-06-08 Therapeutic uses of a c-raf inhibitor

Publications (1)

Publication Number Publication Date
BR112018075371A2 true BR112018075371A2 (pt) 2019-03-19

Family

ID=59215827

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075371-8A BR112018075371A2 (pt) 2016-06-10 2017-06-08 usos terapêuticos de um inibidor de c-raf

Country Status (13)

Country Link
US (1) US20190175609A1 (enExample)
EP (1) EP3468595A1 (enExample)
JP (1) JP2019517549A (enExample)
KR (1) KR20190017767A (enExample)
CN (1) CN109310761A (enExample)
AU (1) AU2017279046B2 (enExample)
BR (1) BR112018075371A2 (enExample)
CA (1) CA3026876A1 (enExample)
CL (1) CL2018003530A1 (enExample)
IL (1) IL262961A (enExample)
MX (1) MX2018015353A (enExample)
RU (1) RU2018146886A (enExample)
WO (1) WO2017212442A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
KR20240032157A (ko) 2017-05-02 2024-03-08 노파르티스 아게 병용 요법
WO2020185516A1 (en) 2019-03-08 2020-09-17 Auris Health, Inc. Tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and applications tilt mechanisms for medical systems and
MX2021013817A (es) 2019-05-13 2021-12-14 Novartis Ag Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
EP4048259A4 (en) 2019-10-24 2023-08-02 Kinnate Biopharma Inc. Inhibitors of raf kinases
WO2021110141A1 (zh) * 2019-12-06 2021-06-10 南京明德新药研发有限公司 Pan-RAF激酶抑制剂的联芳基化合物
CN113912591B (zh) * 2020-07-08 2023-10-20 齐鲁制药有限公司 联芳基化合物
CN117425650A (zh) * 2021-06-04 2024-01-19 齐鲁制药有限公司 一种raf激酶抑制剂的晶型及其制备方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
WO2015119930A1 (en) * 2014-02-04 2015-08-13 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
EP3563870A1 (en) * 2014-07-15 2019-11-06 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors

Also Published As

Publication number Publication date
AU2017279046A1 (en) 2018-12-06
US20190175609A1 (en) 2019-06-13
EP3468595A1 (en) 2019-04-17
CA3026876A1 (en) 2017-12-14
JP2019517549A (ja) 2019-06-24
IL262961A (en) 2018-12-31
WO2017212442A1 (en) 2017-12-14
CN109310761A (zh) 2019-02-05
CL2018003530A1 (es) 2019-02-15
MX2018015353A (es) 2019-09-09
KR20190017767A (ko) 2019-02-20
AU2017279046B2 (en) 2020-07-02
RU2018146886A (ru) 2020-07-10
RU2018146886A3 (enExample) 2020-10-15

Similar Documents

Publication Publication Date Title
BR112018075371A2 (pt) usos terapêuticos de um inibidor de c-raf
CL2019000681A1 (es) Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk.
CL2019003091A1 (es) Terapia de combinación.
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
BR112016012506A2 (pt) Combinações farmacêuticas, seus usos, e uso de um portador de dados
BR112019001818A2 (pt) terapia combinada para câncer
BR112018074155A2 (pt) anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo
AR104812A1 (es) Combinaciones terapéuticas y métodos para tratar neoplasias
BR112022009563A2 (pt) Compostos de pirrolotriazina atuando como inibidor de mnk
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
BR112018009064A2 (pt) anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo
DOP2016000133A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
BR112019003989A2 (pt) métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado
BR112017017078A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença.
BR112018008918A2 (pt) compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
CO2019009586A2 (es) Anticuerpos anti-gitr y métodos de uso de los mismos
HK1254635A1 (zh) C-met抑制剂与pd-1抗体分子的组合及其用途
PT3866767T (pt) Composição farmacêutica para administração oral que inclui um derivado de aminopirimidina ou o seu sal
BR112021008582A8 (pt) Regime de dosagem de anticorpo anti-tigit para tratamento de câncer
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
WO2015191568A3 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
CL2020003306A1 (es) Composiciones bifuncionales para el tratamiento del cáncer.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements